Baricitinib in New-onset Type 1 Diabetes (BANDIT)
A Phase 2, Randomised, Placebo Controlled Study Investigating the Efficacy of Baricitinib in New Onset Type 1 Diabetes Mellitus
Sponsor: Juvenile Diabetes Research Foundation
This PHASE2 trial investigates Type 1 Diabetes and is currently completed. Juvenile Diabetes Research Foundation leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Mar 2021 — Jun 2022 [monthly]
Recruiting PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Juvenile Diabetes Research Foundation
- Juvenile Diabetes Research Foundation Australia
- St Vincent's Institute of Medical Research
For direct contact, visit the study record on ClinicalTrials.gov .